| Source Date | Board Meeting Date | Details |
| 04 May 2026 | 29 May 2026 | Audited Results & Dividend |
| 22 Jan 2026 | 13 Feb 2026 | Quarterly Results |
| 17 Oct 2025 | 13 Nov 2025 | Quarterly Results |
| 24 Jul 2025 | 11 Aug 2025 | Quarterly Results |
| 14 May 2025 | 29 May 2025 | Audited Results & Final Dividend |
| 27 Jan 2025 | 13 Feb 2025 | Quarterly Results |
| 24 Oct 2024 | 14 Nov 2024 | Quarterly Results & Interim Dividend |
| 23 Sep 2024 | 30 Sep 2024 | Inter alia, to consider and approve:- (1) Integration and consolidation of the generics formulations business in the US market of M/s. Bayshore Pharmaceuticals LLC (wholly owned step-down subsidiary) into Unichem Pharmaceuticals (USA) Inc. (wholly owned subsidiary of Company?s subsidiary) |
| 24 Jul 2024 | 13 Aug 2024 | Quarterly Results |
| 07 May 2024 | 29 May 2024 | Final Dividend & Audited Results |
| 23 Jan 2024 | 14 Feb 2024 | Quarterly Results |
| 25 Oct 2023 | 10 Nov 2023 | Quarterly Results & Interim Dividend |
| 21 Jul 2023 | 10 Aug 2023 | Quarterly Results |
| 12 May 2023 | 29 May 2023 | Audited Results |
| 20 Jan 2023 | 14 Feb 2023 | Quarterly Results |
| 02 Nov 2022 | 11 Nov 2022 | Quarterly Results & Interim Dividend |
| 28 Jul 2022 | 10 Aug 2022 | Quarterly Results |
| 12 May 2022 | 24 May 2022 | Audited Results & Amalgamation |
| 31 Jan 2022 | 14 Feb 2022 | Quarterly Results |
| 20 Oct 2021 | 13 Nov 2021 | Interim Dividend & Stock Split & Quarterly Results |
